AKBAAkebia Therapeutics, Inc.

Nasdaq akebia.com


$ 1.38 $ 0.07 (5.38 %)    

Friday, 03-May-2024 15:59:08 EDT
QQQ $ 435.98 $ 8.58 (2.01 %)
DIA $ 386.87 $ 4.54 (1.19 %)
SPY $ 511.25 $ 6.26 (1.24 %)
TLT $ 89.88 $ 0.90 (1.01 %)
GLD $ 212.97 $ -0.17 (-0.08 %)
$ 1.37
$ 1.33
$ 0.00 x 0
$ 0.00 x 0
$ 1.32 - $ 1.41
$ 0.78 - $ 2.48
3,117,001
na
256.83M
$ 1.49
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 03-14-2024 12-31-2023 10-K
2 11-08-2023 09-30-2023 10-Q
3 08-28-2023 06-30-2023 10-Q
4 05-08-2023 03-31-2023 10-Q
5 03-10-2023 12-31-2022 10-K
6 11-03-2022 09-30-2022 10-Q
7 08-04-2022 06-30-2022 10-Q
8 05-09-2022 03-31-2022 10-Q
9 03-01-2022 12-31-2021 10-K
10 11-04-2021 09-30-2021 10-Q
11 08-05-2021 06-30-2021 10-Q
12 05-10-2021 03-31-2021 10-Q
13 02-25-2021 12-31-2020 10-K
14 11-05-2020 09-30-2020 10-Q
15 08-10-2020 06-30-2020 10-Q
16 05-05-2020 03-31-2020 10-Q
17 03-12-2020 12-31-2019 10-K
18 11-12-2019 09-30-2019 10-Q
19 08-08-2019 06-30-2019 10-Q
20 05-09-2019 03-31-2019 10-Q
21 03-26-2019 12-31-2018 10-K
22 11-08-2018 09-30-2018 10-Q
23 08-08-2018 06-30-2018 10-Q
24 05-09-2018 03-31-2018 10-Q
25 03-12-2018 12-31-2017 10-K
26 11-08-2017 09-30-2017 10-Q
27 08-08-2017 06-30-2017 10-Q
28 05-09-2017 03-31-2017 10-Q
29 03-06-2017 12-31-2016 10-K
30 11-09-2016 09-30-2016 10-Q
31 08-08-2016 06-30-2016 10-Q
32 05-05-2016 03-31-2016 10-Q
33 03-14-2016 12-31-2015 10-K
34 11-09-2015 09-30-2015 10-Q
35 08-11-2015 06-30-2015 10-Q
36 05-11-2015 03-31-2015 10-Q
37 03-04-2015 12-31-2014 10-K
38 11-10-2014 09-30-2014 10-Q
39 08-11-2014 06-30-2014 10-Q
40 05-12-2014 03-31-2014 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 hc-wainwright--co-maintains-buy-on-akebia-therapeutics-raises-price-target-to-6

HC Wainwright & Co. analyst Ed Arce maintains Akebia Therapeutics (NASDAQ:AKBA) with a Buy and raises the price target f...

 fda-approves-for-akebia-therapeutics-vafseo-for-kidney-disease-associated-anemia

The FDA-approved Vafseo tablets by Akebia Therapeutics for managing anemia in adult dialysis patients with chronic kidney disea...

 why-rh-shares-are-trading-higher-by-around-9-here-are-20-stocks-moving-premarket

Shares of RH (NYSE: RH) rose sharply in today’s pre-market trading following the release of quarterly results.

 reported-earlier-akebias-wins-fda-approval-of-vafseo-tablets-for-dialysis-related-anemia-treatment

Once-Daily Oral HIF-PH Inhibitor Activates Physiologic Response to Manage Anemia  Akebia's Launch Strategy Developed to ...

 cintas-reports-upbeat-earnings-joins-paysign-noah-holdings-and-other-big-stocks-moving-higher-on-wednesday

U.S. stocks were higher, with the Dow Jones index gaining around 300 points on Wednesday.

 why-westport-fuel-systems-shares-are-trading-lower-by-around-10-here-are-other-stocks-moving-in-tuesdays-mid-day-session

Shares of Westport Fuel Systems Inc. (NASDAQ: WPRT) fell sharply during Tuesday’s session after posting a wider-than-expected ...

 hc-wainwright--co-reiterates-buy-on-akebia-therapeutics-maintains-5-price-target

HC Wainwright & Co. analyst Ed Arce reiterates Akebia Therapeutics (NASDAQ:AKBA) with a Buy and maintains $5 price target.

 akebia-therapeutics-q4-sales-56200m-beat-55393m-estimate

Akebia Therapeutics (NASDAQ:AKBA) reported quarterly sales of $56.200 million which beat the analyst consensus estimate of $55....

 earnings-scheduled-for-march-14-2024

Companies Reporting Before The Bell • Pharming (NASDAQ:PHAR) is projected to report earnings for its fourth quarter.

 akebia-secures-55m-term-loan-financing

 Akebia Therapeutics®, Inc. (NASDAQ:AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted ...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION